Cargando…

The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8(+)T Cell Anti-tumor Activity

The conditionally replicating oncolytic adenovirus Delta24-RGD (Ad) is currently under investigation in clinical trials for glioblastoma, including in combination with temozolomide (TMZ), the standard chemotherapy for this tumor. Previously, we showed that the efficacy of Delta24-RGD in a murine mod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kleijn, Anne, van den Bossche, Wouter, Haefner, Erik S., Belcaid, Zineb, Burghoorn-Maas, Chantal, Kloezeman, Jenneke J., Pas, Suzan D., Leenstra, Sieger, Debets, Reno, de Vrij, Jeroen, Dirven, Clemens M.F., Lamfers, Martine L.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415315/ https://www.ncbi.nlm.nih.gov/pubmed/28480325 http://dx.doi.org/10.1016/j.omto.2017.02.002

Ejemplares similares

The In Vivo Therapeutic Efficacy of the Oncolytic Adenovirus Delta24-RGD Is Mediated by Tumor-Specific Immunity
por: Kleijn, Anne, et al.
Publicado: (2014)

Locally-Delivered T-Cell-Derived Cellular Vehicles Efficiently Track and Deliver Adenovirus Delta24-RGD to Infiltrating Glioma
por: Balvers, Rutger K., et al.
Publicado: (2014)

The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2015)

ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells
por: Balvers, Rutger K, et al.
Publicado: (2015)

The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2014)

Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy
por: Belcaid, Zineb, et al.
Publicado: (2020)

A Systematic Comparison Identifies an ATP-Based Viability Assay as Most Suitable Read-Out for Drug Screening in Glioma Stem-Like Cells
por: Kleijn, A., et al.
Publicado: (2016)

Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies
por: van Putten, Erik H.P., et al.
Publicado: (2022)

Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors
por: Fabro, Federica, et al.
Publicado: (2022)

Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma
por: Ntafoulis, Ioannis, et al.
Publicado: (2022)

TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2
por: Venkatesan, Subramanian, et al.
Publicado: (2016)

A cyclic-RGD-BioShuttle functionalized with TMZ by DAR(inv) “Click Chemistry” targeted to α(v)β(3) integrin for therapy
por: Braun, Klaus, et al.
Publicado: (2010)

OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth()()
por: Towner, Rheal A., et al.
Publicado: (2018)

Effects of the IDH1 R132H Mutation on the Energy Metabolism: A Comparison between Tissue and Corresponding Primary Glioma Cell Cultures
por: Dekker, Lennard J. M., et al.
Publicado: (2022)

Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in glioblastoma
por: Fabro, Federica, et al.
Publicado: (2022)

Delta-24-RGD Oncolytic Adenovirus Elicits Anti-Glioma Immunity in an Immunocompetent Mouse Model
por: Jiang, Hong, et al.
Publicado: (2014)

TRPC5 mediates TMZ resistance in TMZ-resistant glioblastoma cells via NFATc3-P-gp pathway
por: Zou, Yan, et al.
Publicado: (2021)

TMZ-BioShuttle – a reformulated Temozolomide
por: Waldeck, Waldemar, et al.
Publicado: (2008)

High-Resolution Flow Cytometry: a Suitable Tool for Monitoring Aneuploid Prostate Cancer Cells after TMZ and TMZ-BioShuttle Treatment
por: Braun, Klaus, et al.
Publicado: (2009)

Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy
por: Zong, Zhenkun, et al.
Publicado: (2019)

Hsa_circ_0072309 enhances autophagy and TMZ sensitivity in glioblastoma
por: Yuan, Fanen, et al.
Publicado: (2022)

A novel series of phenolic temozolomide (TMZ) esters with 4 to 5-fold increased potency, compared to TMZ, against glioma cells irrespective of MGMT expression
por: Shervington, Leroy, et al.
Publicado: (2020)

Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures
por: Verheul, Cassandra, et al.
Publicado: (2021)

Recent advances in the molecular understanding of glioblastoma
por: Bleeker, Fonnet E., et al.
Publicado: (2012)

Radiosensitization of Glioma Cells by Temozolomide (TMZ): A Colony Formation Assay
por: Babaloui, Somayyeh, et al.
Publicado: (2022)

Phase 1 study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas
por: Newlands, E S, et al.
Publicado: (2003)

SapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma
por: Wojton, Jeffrey, et al.
Publicado: (2014)

Effects of valproic acid on the susceptibility of human glioma stem cells for TMZ and ACNU
por: Li, Zhiying, et al.
Publicado: (2018)

TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ
por: Lu, Hui, et al.
Publicado: (2019)

Antitumor effects of ribavirin in combination with TMZ and IFN-β in malignant glioma cells
por: Ochiai, Yushi, et al.
Publicado: (2020)

Gasdermin D Is a Novel Prognostic Biomarker and Relates to TMZ Response in Glioblastoma
por: Liu, Junhui, et al.
Publicado: (2021)

Experimental study of selective MGMT peptides mimicking TMZ drug resistance in glioma
por: Wu, Yue, et al.
Publicado: (2022)

Local delivery of hrBMP4 as an anticancer therapy in patients with recurrent glioblastoma: a first-in-human phase 1 dose escalation trial
por: Bos, Eelke M., et al.
Publicado: (2023)

Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response
por: Stavrakaki, Eftychia, et al.
Publicado: (2021)

Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
por: Chai, Ruichao, et al.
Publicado: (2021)

317 Omics based analysis to identify novel markers of TMZ response in Glioblastoma Multiforme
por: Reed, Megan R., et al.
Publicado: (2023)

Dysregulated lipid metabolism in TMZ-resistant glioblastoma: pathways, proteins, metabolites and therapeutic opportunities
por: Kao, Tzu-Jen, et al.
Publicado: (2023)

Comparative single-cell RNA-sequencing profiling of BMP4-treated primary glioma cultures reveals therapeutic markers
por: Verploegh, Iris S C, et al.
Publicado: (2022)

Therapeutic effect of TMZ-POH on human nasopharyngeal carcinoma depends on reactive oxygen species accumulation
por: Xie, Li, et al.
Publicado: (2015)

Role of Metformin and AKT Axis Modulation in the Reversion of Hypoxia Induced TMZ-Resistance in Glioma Cells
por: Lo Dico, Alessia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ucf8a8pdeekliqmijf5seb9fgf